Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs iThriveMD

Fitstry
Graded #300

Lower grade

vs+5.5
iThriveMD
Graded #186

Higher grade

The verdict

iThriveMD takes it — 66.7/100 to 61.2/100.

iThriveMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. iThriveMD is a longevity and metabolic-health clinic (physical locations plus telehealth) offering compounded GLP-1 weight loss — semaglutide (from $299/mo) and tirzepatide (from $399/mo), plus microdosing…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueiThriveMD +7
29
36
Dose & formulationFitstry +11
75
64
Clinical oversightiThriveMD +8
81
89
Labs & monitoringiThriveMD +18
73
91
FulfillmentiThriveMD +8
67
75
Contract termsiThriveMD +8
47
55
Fitstry · left bariThriveMD · right bar

The numbers

MetricFitstryiThriveMD
WeighScore61.2/10066.7/100
GradeCC
Scorecard rank#300#186
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)$299/mo (starting dose, compounded)
Tirzepatide$269/mo (annual plan, compounded)$399/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Fitstry

Graded #300 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
iThriveMD

Graded #186 · C

Strengths

  • Compounded semaglutide (from $299/mo) and tirzepatide (from $399/mo), plus microdosing tirzepatide programs
  • Lab testing and personalized protocols with a medical team; free initial consultation
  • Very thorough legal/policy suite (Terms, Privacy, EUA, Shipping, Returns, CCPA)
  • Broad longevity menu: hormones (HRT/TRT), NAD+, peptides, IV therapy, sexual health, diagnostics

Where it loses points

  • Premium pricing — higher than budget compounded-GLP-1 competitors (lowest rates need 'preferred pricing')
  • Headline GLP-1 pricing is 'starting at'; full cost depends on dose and program length
  • Compounding pharmacy partner not named
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard